Eylea Regulatory Post Marketing Surveillance(rPMS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Bayer
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: February 1, 2013
Last updated: August 8, 2016
Last verified: August 2016
The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by KFDA.

Condition Intervention
Macular Degeneration
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Eylea Regulatory Post Marketing Surveillance in Korea

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs) [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart.[BCVA: Best Corrected Visual Acuity] [ Time Frame: 4 months or 8 months ] [ Designated as safety issue: No ]
  • Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography] [ Time Frame: 4 months or 8 months ] [ Designated as safety issue: No ]
  • Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography [ Time Frame: 4 months or 8 months ] [ Designated as safety issue: No ]
  • IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure] [ Time Frame: 4 months or 8 months ] [ Designated as safety issue: No ]
  • Measurement of fundus lesion by fundoscopy [ Time Frame: 4 months or 8 months ] [ Designated as safety issue: No ]
  • Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs) [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 3600
Study Start Date: April 2014
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with wet age-related macular degeneration(wAMD) who are decided to receive EYLEA (VEGF Trap Eye) treatment

Inclusion Criteria:

  • Patients determined to start EYLEA treatment
  • Patients who are prescribed with anti-VEGF therapy for the first time

Exclusion Criteria:

  • Patients who previously received anti-VEGF therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783925

Contact: Bayer Clinical Trials Contact clinical-trials-contact@bayerhealthcare.com

Korea, Republic of
Many Locations, Korea, Republic of
Sponsors and Collaborators
Regeneron Pharmaceuticals
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01783925     History of Changes
Other Study ID Numbers: 16469  EY1310KR 
Study First Received: February 1, 2013
Last Updated: August 8, 2016
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on August 22, 2016